Free Submission Public Relations &
Deutsch English

ISIS Pharma - Picture Beyond KYNAMRO - Targeting Other Niche Indications

ISIS Pharma - Picture Beyond KYNAMRO - Targeting Other Niche Indications - new market research report published

Print article Print article
2014-03-14 08:34:01 - ISIS Pharma - Picture Beyond KYNAMRO - Targeting Other Niche Indications - a new market research report on

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous - HoFH; PhIII for heterozygous familial hypercholesterolemia -HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty. Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains.

Successful systemic delivery of more drugs to the target organs other than liver is the acid test that all antisense/ RNAi focused companies have to pass. ISIS has a robust cash position, valuable IP assets, and success of a few drugs in the current pipeline could accelerate the transformation from a discovery to a pharma company and help it to grow beyond KYNAMRO

Click for report details: ..

Browse all Healthcare and Medical Market



Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact